Molnupiravir was associated with a significantly reduced mortality hazard (HR 0.75, 95% CI 0.58-0.96) among patients with composite organ dysfunction, and a marginally significant reduction (HR 0.69, 95% CI 0.46-1.02) among patients with respiratory failures.
← all excerpts
Effectiveness of Antivirals Nirmatrelvir-Ritonavir and Molnupiravir in Viral Sepsis: Retrospective Cohort Study.
1
—
—